Oestrogen Replacement Therapy for Prevention of Osteoporosis after Oophorectomy
Oestrogen Replacement Therapy for Prevention of Osteoporosis after Oophorectomy
复制标题
雌激素替代疗法预防卵巢切除术后骨质疏松症
作者：
J. M. Aitken;D. Hart;R. Lindsay
对114名中年妇女进行了雌激素治疗预防卵巢切除术后骨质疏松症的价值评估，这些妇女参加了一项平均每日剂量为23 μg的美雌醇双盲对照试验。通过光子吸收技术测量骨骼对治疗的反应。如果在手术后两个月内开始治疗，则可以防止随后的骨矿物质丢失。卵巢切除术后三年开始治疗，导致骨矿物质含量显著增加。当治疗延迟6年时，美雌醇未能阻止随后的骨矿物质随年龄的丢失。这些影响发生独立的钙和磷稳态相关的体液变化。这种剂量的美司特雷诺似乎是相对安全的，但现在评估这种治疗的长期危害还为时过早。
The value of oestrogen therapy in the prevention of osteoporosis after oophorectomy was assessed in 114 middle-aged women who participated in a double-blind controlled trial of mestranol in an average daily dose of 23 μg. The skeletal response to treatment was measured by a photon absorption technique. Where treatment was started within two months of operation subsequent bone mineral loss was prevented. Treatment started three years after oophorectomy caused a highly significant increase in bone mineral content. When treatment was delayed for six years mestranol failed to prevent subsequent bone mineral loss with age. These effects occurred independently of the associated humoral changes in calcium and phosphorus homoeostasis. Mestranol in this dosage appeared to be relatively safe, but it is too early to evaluate the long-term hazards of such therapy.